
Sign up to save your podcasts
Or


Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.
By Venrock, a venture capital firm4.8
6262 ratings
Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.

1,287 Listeners

2,704 Listeners

2,461 Listeners

1,094 Listeners

339 Listeners

334 Listeners

389 Listeners

5,568 Listeners

10,086 Listeners

35 Listeners

532 Listeners

21 Listeners

291 Listeners

473 Listeners

1,442 Listeners